Top 50 Life Science VC Funds & Investors (June 2026)

Portfolio highlights

• MixRift — MIXRIFT - game developers specialized in Mixed Reality
• unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
• Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.

Portfolio highlights

• Ultivue — Ultivue is a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing. Ultivue produces reagents that enable researchers to obtain microscopic images at an unprecedented resolution that helps to understand of biology and medicine. Ultivue's products are designed for fluorescent microscopy-based research and willeventually be valuable for clinical diagnostic use. It was founded in 2015 and headquartered in Cambridge, Massachusetts.
• EGenesis — At eGenesis, we envision a world where transplantation is accessible to all. We develop safe and effective human-compatible organs for transplantation.
• Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.

Portfolio highlights

• EndoRon Medical — Endoron Medical develops an endovascular suture, like a device for the effective treatment of an abdominal aortic aneurysm.
• BrightHeart — BrightHeart develops an AI-based platform for fetal ultrasound analysis to improve detection of congenital heart defects.
• Forth Therapeutics — Forth Therapeutics is a biotechnology company dedicated to advancing precision treatments for fibrosis.

Portfolio highlights

• miRecule — MiRecule is an early-stage biotechnology company that focuses on developing microRNA-based therapeutics. It features a genomic-based drug development platform that integrates genomic sequencing, expression, and prognostic data from cancer patients. The company was founded in 2016 and headquartered in Gaithersburg, United States.
• Marvin Health — Marvin is a mental health service for physicians. We're ending the one-size-fits-all approach to teletherapy, helping you to set a teletherapy action plan.
• Deep Genomics — Revolutions in AI, biology and automation are enabling a new approach to medicine. Deep Genomics is at the forefront.

Portfolio highlights

• Vizgen — Vizgen is a privately held biotech company developing the next generation of spatially resolved, single-cell transcriptomics technology and toolbox. The company's patented MERFISH technology enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and detection efficiency at subcellular resolution. The highthroughput and resolution and the low cost per cell achieved by the technology will enable a wide range of tissue-scale basic research and development and will be instrumental to efforts to discover and map cell types and states in a range of tissues and organisms.
• Culture Biosciences — Culture Biosciences develops automated bio-reactor that helps biotech companies optimize their manufacturing processes and brings products to market faster. The company also builds automated tools for fermentation. It has a digital bio-manufacturing platform to enable scientists to run, monitor, and analyze bio-reactors faster than traditionalapproaches by robotic sample handling and cloud data monitoring and analysis.Culture Biosciences was founded in 2016 and is headquartered in San Francisco, California.
• Scipher Medicine — At Scipher Medicine, we are committed to transforming the way providers prescribe drugs, as well as the way manufacturers, develop new drugs. We have built a molecular map of all protein interactions that identifies genomic signatures and links those to disease and predictive treatment outcomes. Using a simple blood sample to analyze RNA, we canpredict if a patient is likely to respond to a targeted therapy before therapy is prescribed. This insight allows patients to start the most effective therapy from day one. For our first commercial product, we have developed PrismRA®, a first-of-its-kind blood test that can predict which patients with rheumatoid arthritis are less likely to respond to TNFi therapies such as Humira® and Enbrel® so that such patients can go on alternative approved drugs.We also used a different one for the ACO Payer Summit, I’ve provided that as well: Scipher Medicine is building the future of patient treatment. Most patients who are prescribed blockbuster therapies today don't respond to treatment, costing the healthcare industry billions in wasted drugs while patients continue to suffer. Scipher's platform identifies which drug will work based on the patient's fundamental disease biology, and not based on symptoms, disease classification, or medical bias. A routine blood test predicts which drug he/she will respond to, with our first product focusing on rheumatoid arthritis, ensuring that the most optimal treatment is prescribed from day one. The molecular data generated by our tests is then used to fuel novel target discovery to address a clear unmet medical need in patients who do not respond to any existing therapy.

Portfolio highlights

• Galecto — Damora Therapeutics is working to fundamentally redefine care for people with blood disorders by bringing forward optimized therapies that dramatically improve patient outcomes.
• Insilico Medicine — Artificial Intelligence for Drug Discovery and Aging Research
• Aspen Neuroscience — personalized cell therapy Starts with you Learn More about our technology

Portfolio highlights

• Smarterer — Individuals and Fortune 500 companies use Smarterer to help close the gap between the skills they have and the skills they need. Their dynamic assessment engine leverages the freshest crowdsourced tests around, to rapidly pinpoint skill level with a credible score. In November 2014, Pluralsight, the global leader in online learning for serioussoftware developers, IT specialists and creative technologists, acquired Smarterer. As the world's largest curated e-learning library for professionals, the company offers instant access to more than 3,500 courses authored by top experts. Smarterer will continue to power crowdsourced assessments for freelancer marketplaces, e-learning providers and enterprise companies anywhere people need to prove their skills to connect with professional opportunities. The Smarterer community has answered over 56 million during 1.7 million test sessions, across hundreds of tests.
• Zest — Give your shoppers the swiftest gifting experience in ecommerce. With Zest, shoppers on your site can send a gift to anybody, anywhere with just a link.
• EpiBiologics — EpiBiologics develops first-in-class antibody based targeted therapies against membrane and extracellular proteins that drive underlying disease biology.

Portfolio highlights

• Splice Bio — Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.
• Bionano Genomics — Discover how Bionano is striving to elevate health and wellness for all through optical genome mapping (OGM) solutions that transform the way the world sees the genome.
• LOQUS23 THERAPEUTICS — LoQus23 is a DDF-formed company focussing on targeting DNA damage repair pathways to treat Huntington’s disease and other triplet repeat diseases.

Portfolio highlights

• Mogrify — Mogrify is pioneering a new class of in vivo reprogramming therapy and transforming the development of ex vivo cell therapy.
• PhoreMost — PhoreMost is a new-model drug discovery company based in Cambridge, UK: Using its core expertise to open up new ‘druggable’ target space and working with a global network of co-invested academic and industrial collaboration partners, we aim to bring a wide array of novel ‘targeted’ therapies more efficiently to market and pass these cost savingsonto patients.
• Bramble Energy — Bramble Energy is an innovator energy technology company that designs and manufactures high-performance, low-cost, and fuel cell stack. The company ability to leverage the global high-volume PCB industry means that they are the first fuel cell company with the manufacturing capacity to supply gigawatts of fuel cell hardware, something the batteryindustry has spent many years and £B’s to achieve.Bramble Energy specifically uses a printed circuit board (PCB) technology to form the structural parts of the fuel cell. It also provides products including modular PCBFC stacks, H20:20W PCBFC system, custom design PCBFC, and 500W PCBFC stack.Bramble Energy was founded in 2016 and is based in London, England, United Kingdom.

Portfolio highlights

• ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
• Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases.
• Terrestrial Bio — Vaxess engineers novel technologies that uniquely engage the human immune system, enabling improved efficacy and simplified access for vaccines and therapeutics.

Portfolio highlights

• Verkor — Verkor is a battery cell manufacturer whose goal is to increase the production of low-carbon batteries to fulfill the growing demand for electric vehicles. The company focuses on the development of low-carbon batteries with a carbon footprint that is many times smaller than standard batteries. This reduces the logistics footprint, includingemissions, and provides businesses with batteries that are very inexpensive and use carbon-free electricity.
• WAAT — WAAT operates fast charging stations for electric and rechargeable hybrid vehicles. Its services are aimed at all private sector market segments, including condominiums, lessees, tertiary, and real estate development. The company was founded in 2018 and is based in Paris with sales offices in Malakoff and Bagneux (92).
• BiPER Therapeutics — BiPER Therapeutics is a biotech company to develop and commercializes novel therapeutics.

Portfolio highlights

• Judo Bio — Judo Bio is pioneering oligonucleotide medicines delivered to the kidney, opening the way for new treatments for systemic and renal diseases.
• Nimbus Therapeutics — Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinicaldevelopment. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.
• Remix Therapeutics — Remix Therapeutics is a biotechnology company that develops novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways.

Portfolio highlights

• Anjuna — Anjuna confidential cloud software establishes a secure enclave that isolates and encrypts applications and data in runtime, at rest, and on the network for end-to-end data protection
• Biolinq — Introducing a revolutionary platform for metabolic health.
• Asceneuron — Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.

Portfolio highlights

• Turning Point Therapeutics — The Investor Relations website contains information about Turning Point Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
• Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
• River Vision Development — River Vision Development develops RV001, a protein therapy for the treatment of Graves’ Orbitopathy (GO). River Vision Development was founded in 2011 and is based in New York, New York.

Portfolio highlights

• CytomX Therapeutics — CytomX Therapeutics is a biotechnology company that focuses on developing proteolytically-activated antibodies. Their mission, alone and with the help of partners, is to provide patients with more effective and less toxic therapies for severe illnesses such as cancer and inflammatory diseases.
• Rapport Therapeutics — Precision medicines to match the complexity of the human brain.
• Synnovation Therapeutics — Synnovation Therapeutics is a precision oncology company focused on small molecule therapies optimized to target key driver mechanisms in cancers. It is dedicated to the discovery and development of therapeutics that can improve the lives of people with cancer. Leveraging its deep expertise in medicinal chemistry, cancer biology, andpatient-focused precision medicine, it builds a diverse pipeline of novel small-molecule targeted therapies. It aims to efficiently advance these agents into clinical trials with the goal of transforming cancer patient care.

Portfolio highlights

• ZwitterCo — ZwitterCo is revolutionizing water & wastewater treatment with cutting-edge membrane technology, along with providing sustainable, high-efficiency solutions.
• Jupiter Intelligence — The Trusted Leader in Climate Risk Analytics. Learn about our best-in-science solutions.
• Relation Therapeutics — Relation uses machine learning to develop drugs for pressing unmet need.

Portfolio highlights

• Pepgen — PepGen empowers nucleic acid therapeutics to go the distance. PepGen's ambition is to unlock the potential of nucleic acid therapeutics by leveraging the drug delivery capabilities of their innovative product engine. PepGen's initial focus is on the application of this technology to the efficacious delivery of antisense oligonucleotides,and they are advancing novel conjugate therapeutics to the clinic.
• Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
• Quantum Motion — Quantum Motion delivers scalable silicon-based quantum computing using standard semiconductor manufacturing technology.

Portfolio highlights

• HonuWorx — HonuWorx is a subsea robotics company founded with a mission to replace surface vessels with underwater deployment platforms.
• NanoSyrinx — NanoSyrinx is an award-winning, discovery stage biotechnology company based in the UK. We are using synthetic biology approaches to develop protein nanosyringes as a completely novel modality for intracellular delivery of protein and peptide biologic drugs.
• Aquark Technologies — Aquark Technologies develops atom systems to develop quantum applications, including atomic clocks, sensors, and navigation systems. Aquark develops a technique to miniaturize cold atom systems using unique laser geometry that is based on more than 10 years of proprietary research at the University of Southampton.

Portfolio highlights

• Farcast — Unlocking satellite internet capacity through user terminal innovation
• Solugen — Solugen's mission is to decarbonize the chemicals industry. Solugen combines synthetic biology with metal catalysis to make carbon negative chemicals at scale.Solugen's patented approach takes advantage of bio-inspired reactions to use plant material as a low-cost feedstock to produce novel products cost-competitive with thecompetition.
• Valence Discovery — Empowering drug discovery scientists with the latest advances in AI-enabled drug design

Portfolio highlights

• Nest Health — Nest Health is a primary care company that offers whole person, whole family care for families from birth through age five in urban areas. Nest offers primary and pediatric care for families, made affordable and convenient.
• Hello Patient — Healthcare AI that gets your team off the phone & in front of patients
• Better Health — Better Health is a Modern Medical Supplier focused on delivering Urology & Ostomy Supplies. Shop the latest Catheters, Ostomy Bags from Hollister, Convatec, Coloplast and many more.

Portfolio highlights

• Stablix — Stablix is pioneering an entirely new field of targeted protein stabilization (TPS) to bring transformative medicines to patients with unmet medical need.
• Passage Bio — Passage Bio, a genetic medicines company, is changing the future of CNS disorders and transforming the lives of patients and their families.
• Lycia Therapeutics — Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA.

Portfolio highlights

• AlloCure — AlloCure is a biotechnology company, develops cell therapies for the treatment of various kidney diseases, organ transplants, and multi-organ injuries. It offers biological therapeutics for acute kidney injuries. AlloCure is based in Burlington, Massachusetts. It has operations in Salt Lake City, Utah, and Hamburg, Germany.The company isdedicated to the development of off-the-shelf biological therapies to treat serious and debilitating diseases that afflict millions of people around the world. AlloCure's unique technology uses processed cells derived from human bone marrow to treat a wide variety of diseases. AlloCure was founded on the unique and proprietary technology developed by Dr. Christof Westenfelder and Dr. Axel Zander. Westenfelder and Zander are world-renowned scientists who have dedicated their careers to developing effective therapies for kidney disease. AlloCure has operations in Salt Lake City Utah and Hamburg Germany.
• PTC Therapeutics — Translating Science. Transforming Lives.
• Breye Therapeutics — Breye Therapeutics, a Danish-based biopharmaceutical firm in the clinical stages, is working to provide cutting-edge oral treatments for the management of retinal vascular diseases.

Portfolio highlights

• OxCan — Enabling curative cancer treatment through early detection
• Wyndly — Retrain your allergies through sublingual (under-the-tongue) treatment plans. Virtual appointments. Treatment delivered. Get started after your first consult with a board-certified doctor for $49.99.
• Foresight Diagnostics — We develop innovative diagnostics to advance decision-making in oncology drug development and patient care.

Portfolio highlights

• Shapeways — Shapeways is the #1 online 3D printing service company. Working with over a million customers since 2007 - Get 3D products and parts delivered to over 100 countries.
• Dapper Labs — Dapper Labs uses the power of play to deliver blockchain-based experiences that are made for you and ready for the real world.
• Genesis Molecular AI — Their academia-leading research was the initial component of our expanding portfolio of AI technologies. They are combining novel deep neural networks, biophysical simulation, and massively scalable computing infrastructure to achieve industry-leading performance in a molecular generation and property prediction.The company was founded in 2019and based in South San Francisco, California.

Portfolio highlights

• iOrganBio — iOrganBio is a pioneering cell production platform that uses CellForge to facilitate the intelligent manufacturing of human cells and organoids.
• Galatea Bio — Galatea Bio, a US-based biotechnology company was founder by Carlos Bustamante, Nicholas Katsanis and Alexander Ioannidis. Our mission is to drive groundbreaking discoveries in healthcare by pairing genetic diversity with cutting-edge data analytics. Our passion is fueled by a focus on populations historically underrepresented in genetics research.We achieve this by leveraging our world-class clinical network and biobank, cutting-edge algorithms, and innovative analyses to discover and validate new tests, treatments, and cures that will improve the lives of all.
• Italic Health — Italic Health, Inc. is a healthcare technology company building a unified platform for managing patient data, medical billing, and insurance workflows. Its software integrates health records, appointment scheduling, and AI-driven analytics to improve care coordination, financial processes, and patient engagement.

Portfolio highlights

• Ousia Pharma — Ousia Pharma is paving the way for novel therapeutic strategies using peptide-drug-conjugates
• Andrew Alliance — OneLab is laboratory software to design and execute liquid handling protocols. Pipette+ for manual liquid handling pipetting and Andrew+ the pipetting robot
• NRG Therapeutics — energizing drug discovery in neurodegenerative diseases.

Portfolio highlights

• Plexium — Plexium harnesses a differentiated platform of proprietary technologies and approaches to establish a robust and diverse portfolio.
• Clarifai — Clarifai is the leading Machine Learning, Computer Vision, NLP Platform. Label, train, deploy models on one AI platform for developers & data scientists.
• Primer — Primer makes powerful mission-ready AI software designed to work in your environment, on your data. We help national security teams sift through massive unstructured data sets to find the needle in the haystack, understand and visualize their data, and act collaboratively. Our mission is to empower decisions that can be defended, and acted upon confidently.

Portfolio highlights

• F2G — F2G is a biopharmaceutical company developing novel therapies for life-threatening fungal infections.
• Noema Pharma — DRIVING BETTER OUTCOMES Advancing therapeutics designed to deliver superior clinical benefit across both orphan and broader neurology indications Who we are ...
• Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.

Portfolio highlights

• Medlumics — Medlumics is a medical device start-up born in 2009 from a compromise with improving human living standards by means of technology.
• Vico Therapeutics — Pioneering RNA-based science to target the root cause of rare genetic neurological diseases VO659: The first clinical candidate directly targeting the CAG repea
• Synendos Therapeutics — Synendos Therapeutics is a biopharmaceutical company that aims to develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of natural functioning of the brain.

Portfolio highlights

• DotBio — DotBio is a biopharmaceutical company specialized in next-generation domain antibody therapies.
• Coastar Therapeutics — Coastar Therapeutics develops an erythrocyte enveloped virus delivery technology platform to perform repeated virus dosing. It evades recognition and attack by the immune system to address the challenges of systemic and repeated administration of drug therapies. Coastar's process technology and “red blood cell membranes only” enable thecompany to overcome the challenges of mass production and standardization, and has cost advantages. The company's first product targets oncolytic viruses and is developing ELCV solutions for other therapies.The company was founded in 2017 and is based in San Diego, CAlifornia.
• Leadinno Medical Valley — Leadino Medical Valley is a producer of medical devices for neuroregulatory functions.

Portfolio highlights

• Pylon — Talk to your customers over Slack, Microsoft Teams, or Discord? Meet Pylon. We'll help you scale your sales, success, and support processes over chat and integrate that data back into your existing systems.
• ClearSky Data — ClearSky Data’s global storage network simplifies the entire data lifecycle and delivers enterprise storage as a fully managed service.Its storage is designed for business agility. ClearSky simplifies enterprise storage by providing an SLA-based managed service across the global network. The company's patent-pending Smart Tiered Cachingcontinually categorizes data and places it in the right cache layer (hot, warm, cold) based on evolving usage requirements and customer policies. Customers simply scale as needed, using the ClearSky dashboard to add unlimited capacity with a few clicks. All data can be moved across the ClearSky network to meet a variety of use cases including data center migration, load balancing, expansion into new regions, or disaster recovery. ClearSky has partnered with major public clouds to place hot and warm cache copies at the cloud edge. The result: customers get low-latency access to cloud instances, providing a new cost-effective option to run their most demanding workloads.The total cost of ownership (TCO) of storing data using the ClearSky service is about 1/3 the cost of managing it in a company’s data center on physical storage arrays.By leveraging the architecture and building redundancy into all cache layers and network paths, ClearSky is able to provide an enterprise-class service with guaranteed high availability. Industry-leading security technologies and best practices ensure that customer data is always protected and isolated from the moment it enters the ClearSky network. Customers simply plug into the ClearSky service to get the storage they need, when and where they need it, with the security, scalability, and resilience that a business depends on.
• Ping Identity — Ping Identity provides cloud-based identity management software for companies and government organizations. They help enterprises achieve Zero Trust identity-defined security & more personalized, streamlined user experiences. The Ping Intelligent Identity Platform provides customers, employees, partners, and, increasingly, IoT, with access tothe cloud, mobile, SaaS, and on-premises applications and APIs, while also managing identity and profile data at scale. Ping Identity was founded in 2002 and headquartered in Denver, Colorado.

Portfolio highlights

• Triveni Bio — Triveni Bio is at the forefront of human genetics, cutting-edge antibody design, and precision medicine, pioneering the identification of new disease targets.
• Axonis Therapeutics — AXONIS Therapeutics, Inc. is advancing breakthrough discoveries to develop first-in-class therapies for neurological disorders.
• Rapport Therapeutics — Precision medicines to match the complexity of the human brain.

Portfolio highlights

• Classiq Technologies — A software platform that helps users create scalable complex quantum computer algorithms, software, and circuits for any gate-based quantum computer
• Eclypsium — Eclypsium's platform enhances supply chain security by incorporating zero-trust in every device, fortifying hardware, firmware, and software.
• Veda — Veda is the largest vault infrastructure platform in DeFi, enabling institutions to launch and manage onchain financial products at scale.

Portfolio highlights

• LookSharp — The industry leader for qualified and diverse candidates to get discovered and hired. Search for job and internship opportunities, access career advice, and connect directly with top employers.
• Practice Fusion — 'Deliver better care more efficiently with the #1 electronic health record. Our industry-leading EHR was developed with feedback from over 150,000 professionals.'
• Second Front Systems — The continuous accreditation and deployment of commercial software is crucial for U.S. national security missions. With Second Front Systems' Game Warden platform, you'll be achieving exactly that.

Portfolio highlights

• Scopely — Scopely is a global interactive entertainment and mobile-first games company, home to many top-grossing, award-winning franchises including “Star Trek™ Fleet Command,” “MARVEL Strike Force,” “Scrabble® GO,” “WWE Champions” and “Yahtzee® With Buddies,” among others. Scopely creates, publishes and live-operates immersive games that empower adirected-by-consumer™ experience. Founded in 2011, Scopely is fueled by a world-class team and a proprietary technology platform Playgami that supports one of the most diversified portfolios in the mobile games industry. Recognized multiple times as one of Fast Company’s “World’s Most Innovative Companies,” Scopely is a multi-billion-dollar business due to its ability to create long-lasting game experiences that players enjoy for years. Scopely has global operations across 17 markets (Asia-Pacific - Bangalore, Seoul, Shanghai, Singapore, Tokyo; EMEA - Barcelona, Dublin, Helsinki, Kyiv, London, Seville, Tel Aviv; North America - Boston, Boulder, Culver City, Mountain View, San Francisco), with additional game studio partners across four continents. For more information, visit www.scopely.com.
• Synthace — The Synthace Experiment Platform lets you design powerful experiments, run them in your lab, & gather automatically structured datasets. No code necessary.
• Amper Music — Amper is an AI music composition company that develops tools for content creators of all kinds. Learn about our new enterprise platform, Score, as well as our creator API.

Portfolio highlights

• Avava — Avava is a Pioneer precision skin therapy to improve the quality of life for patients around the world.
• OSPRI — Multiplex qPCR reagent kits for assay development, biomarker discovery, and translational research. 120+ configurations across a broad range of research areas. Extraction-free. Customizable. For Research Use Only.
• Medical Informatics — Medical Informatics offers solutions that give care teams access to the data they need to take action for alarm management and safety. The company’s Sickbay software platform enables continuous data collection from a comprehensive set of devices. Ultimately their alarm management solutions reduce alarm noise at the patient level, and send the rightalarms to care providers.Medical Informatics Corp was founded by Emma Fauss and Craig Rusin in 2010 and is based in Houston, Texas.

Portfolio highlights

• AveXis — Discover how Novartis Pharmaceuticals brings innovative medicines to market to enhance health outcomes for patients and offer solutions to healthcare providers.
• Bonum Therapeutics — We have created a new class of antibody-regulated protein therapeutics activated only at disease sites, advancing cancer care and exploring broader indications.
• BlueLight Therapeutics — BlueLight Therapeutics uses a proprietary structure-based platform to discover small molecules against difficult-to-drug targets.BlueLight Therapeutics leverages a proprietary, structure-driven platform to develop novel therapeutic molecules against challenging, high-value drug targets. The company has a passionate and experienced team withunique expertise on developing structural assays across a broad range of target classes.

Portfolio highlights

• Elegen — Skip cloning with the only entirely cell-free DNA synthesis provider. Sequences up to 7 kb. Error rates as low as 1:70,000/bp. Manufactured in USA, NGS-verified and shipped globally in as few business days.
• Checkerspot — A biology-driven platform creating specialized lipids from fermentation
• Tierra Biosciences — Speed, scale and simplicity with protein synthesis on-demand. Discover your portal to thousands of custom proteins. Get testable material with a single input.

Portfolio highlights

• Caelux — Solar: Amplified Caelux is a pioneer in utilizing perovskites to make solar energy more powerful and cost-effective, enabling the next generation of solar innovation. PV 3.0 is Here. As competing technologies battle it out to improve solar return on
• Even — Even is a health tech company and healthcare provider that partners directly with the top hospitals in the country to offer you unlimited diagnostics, consultations, and 50 lakh worth of hospitalisations all with one monthly subscription cost.
• Loop — Loop Health is bringing ease and choice to patients seeking major medical treatments. We've brought together family physicians, top specialists, and leading hospitals in Pune – to provide options, transparency, and ease to patients and their families. Loop Coordinators help patients match with a doctor, compare treatment costs, get secondopinions, and complete admission formalities – removing the stress and making lives easier for the patient and their families.

Portfolio highlights

• Montai Therapeutics — Harnessing untapped diverse chemistry with AI-enabled drug discovery to develop breakthrough small molecule medicines for chronic disease.
• Quotient Therapeutics — Discover how Quotient is pioneering a new field of genetics with somatic genomics to unveil a universe of genetic information and develop new therapies.
• Ampersand Biomedicines — Ampersand is enabling potent mechanisms to treat disease by creating and programming therapeutics that are more efficacious, without compromising on safety or tolerability.

Portfolio highlights

• Ribometrix — The Next Frontier of Drug Discovery
• Contego Medical — Better Outcomes. Simplified. Neurovascular Peripheral Vascular Neurovascular
• G1 Therapeutics — G1 Therapeutics is a clinical-stage company developing novel cancer therapies. It was founded in 2008 by Drs. Norman Sharpless and Kwok-Kin Wong to capitalize on discoveries made and patented by Dr. Sharpless’ lab at the University of North Carolina at Chapel Hill, and subsequently licensed to G1 Therapeutics. Trilaciclib is an investigationaltherapy designed to improve outcomes for people with cancer who are treated with chemotherapy. G1 is also advancing rintodestrant, a potential best-in-class oral selective estrogen receptor degrader, or SERD, for the treatment of ER+ breast cancer.

Portfolio highlights

• StrideBio — StrideBio is a gene therapy company focused on developing genetic medicines with curative potential for patients with devastating conditions. It leverages its proprietary structure-inspired adeno-associated virus (AAV) vector engineering platform to create unique and differentiated vectors that improve upon naturally occurring AAV serotypes toovercome current limitations of first-generation gene therapies. The company was founded in 2015 and is headquartered in Durham, North Carolina.
• Xilio Therapeutics — WhatsApp Group Invite
• Accipiter Biosciences — Accipiter Biosciences is a biotechnology company.

Portfolio highlights

• Chiasma — We are a commercial stage pharmaceutical company focused on developing and delivering innovative new treatments that help improve the lives of people with rare diseases.
• Syndax Pharmaceuticals — Syndax Pharmaceuticals is a clinical-stage pharmaceutical company that focuses on an HDAC inhibitor for solid tumors and hematological tumors. It offers therapies to treat solid tumors and lung, breast, and hematological cancer. The company is developing axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor,in development for chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor.Syndax Pharmaceuticals pipeline includes and SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, in development for the treatment of patients with MLLr and NPM1 acute leukemias.
• Portola Pharmaceuticals — As Alexion, AstraZeneca Rare Disease, we are delivering life-changing therapies to people living with rare diseases.

Portfolio highlights

• Adlai Nortye — Adlai Nortye is a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with its R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, it has built a global pipeline through collaborations and internal discoveries with more than 10 drug candidates indevelopment.
• Apella Technology — Apella is an AI startup that brings modern engineering to improve surgery. It collects data from operating rooms in hospitals via sensors and puts artificial intelligence to the task of analyzing that information and spits it out in a way that that the startup says can be interpreted by hospitals to improve operations, surgical quality, training,and even real-time decision-making.Apella was founded in 2019 and is headquartered in San Francisco, California.
• Parabilis Medicines — Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach.

Portfolio highlights

• Violet Therapeutics — Violet Therapeutics is a healthcare company that operates in stealth mode.
• Montara Therapeutics — Montara Therapeutics is a precision-medicine neuroscience biotech startup improving safety and efficacy of therapies for people with neurological diseases
• Harness Therapeutics — Transine Therapeutics is a private biotechnology company focused on the development of a novel class of therapeutic RNAs that can upregulate protein expression with an unprecedented level of control and specificity: the SINEUPs®. The company's pioneering technology is expected to offer an entirely unique mechanism of action for currentlyhard-to-treat diseases by massively extending the druggable proteome and allowing it to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies.

Portfolio highlights

• Samp — Whatever the scale, age, or number of facilities, Shared Reality helps industrial operators accelerate their digital twin programs in an affordable and accessible way.
• FinMarie — FinMarie is an online financial platform for women for women in Germany. The firm supports clients with financial and wealth management projects and helps them find solutions appropriate for their personal situation.
• GeneQuine Biotherapeutics — GeneQuine Biotherapeutics designs and develops gene therapies for its clients. The therapies developed by the company aim to treat osteoarthritis. Its product portfolio consists of GQ-201, GQ-202, and GQ-203. GeneQuine Biotherapeutics was founded in 2011 by Stanislav Plutizki and Kilian Guse.

Portfolio highlights

• Spry — Simplify your physical therapy practice with SPRY. Our all-in-one software streamlines billing, EMR, documentation, and insurance verification. Experience the SPRY difference today.
• Simon Data — Simon Data empowers CRM teams with the data, tools, & support to drive personalization at every customer touchpoint.
• CHARM Therapeutics — CHARM Therapeutics uses deep learning on 3D molecular configurations to develop molecule therapeutics to target pathogenic proteins.

Portfolio highlights

• Sentryc — Protect your brand and your products from counterfeiters with Sentryc. We monitor over 120 marketplaces for you and remove potential counterfeits.
• Flexvelop — Flexvelop combines financial technology with circular economy to add innovative values to the core function of equipment funding.Local vendors and online-shops integrate Flexvelop as a seamless embedded payment option. Business customers are now able to #flex new equipment per click right at the point of sale. Insurance is already covered, andour customers have now the weekly option, to buy- or return their equipment, easily. This enables a new world of worry-free and flexible business growth.We #flex business equipment from €300 up to €20.000 per item; e.g. coffee-machines, laptops, gym- or dental-equipment,... anything you need for your business.NEXT GENERATION PAYMENTS + Technological Innovation: fully automatic embedded payment option + Economical Innovation: optionality (rent/buy/return) + insurance included + Ecological Innovation: sustainability (contributing to a circular economy) = Enabling worry-free flexible business developmentForget renting. Forget leasing. Grow smart - flex it!
• Vertero — Axial Therapeutics is a biotechnology company fundamentally changing the treatment of neurological diseases and disorders by harnessing groundbreaking science in the microbiome-gut-brain axis.

Portfolio highlights

• Carble — We provide carbon insetting technology to tropical commodity buyers and cash incentives to farmers that protect the forest. Our satellite-powered platform monitors carbon emissions, allowing for deforestation-free farming to be rewarded at scale.
• Sapyen — We take the fear out of infertility for men. Test for it at home, without stepping out to the hospital and get personalised health recommendations to improve sperm health and increase your chances of conceiving.
• One Key Access — One Key Access is an interface to the world of couriers to enable 24/7 frictionless deliveries.

Portfolio highlights

• Neuronetics — Antidepressant medications don't work for everyone. If drugs haven't worked for you, learn about NeuroStar - safe, effective, lasting TMS therapy for depression.
• Triana Biomedicines — Triana Biomedicines is building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. Triana’s drug discovery engine is powered by high- resolution structural insights, state-of-the-art in silico tools, and bespoke chemical libraries. The research team has validated thebest-in-class platform and initiated multiple programs across different disease areas.
• ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.